mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
The vaccine reportedly thwarted the cancer's return and spread.
Ars Technica2 sources
Published by CurrentWire · First coverage · Latest coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Ars Technica and The Hill.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
2 publications are covering this story.
Excerpts are the summaries each publisher distributes with its own feed, shortened and attributed.
Ars TechnicaTier B
mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say(opens original report in a new tab)The HillTier B
Moderna, Merck mRNA cancer vaccine prevents melanoma from returning(opens original report in a new tab)An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced… — The Hill
How coverage developed
First report from The Hill
Reported by Ars Technica
Story updateHeadline updated
Story updateArs Technica joined coverage
Story updateCoverage went from 1 to 2 sources
How CurrentWire compiled this story
Ars Technica (arstechnica.com), a Tier B publisher, filed this report on . CurrentWire published this page 1 minute later, on .
Signal breakdown
CurrentWire ranked this story 67.4 of 100 in the snapshot this page was rendered from.
- Freshness
- 30.9 of 35
- Source authority
- 14 of 20
- Coverage breadth
- 8.5 of 20
- Geographic relevance
- 3.5 of 10
- Story prominence
- 8 of 10
- Velocity
- 2.5 of 5
Strongest signal: freshness, 30.9 of 35. How each signal is calculated.
Filed under Health · International · News.
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.